Becanex's plant-identical cannabis concentrates reflect the natural ratio of cannabinoids and terpenes found in the flower. Many patients appreciate the different terpene profiles, which is why our portfolio includes several THC and CBD concentrates – each with a stable, characteristic profile.

The products in the PIEX portfolio can be combined with one another. The targeted selection of cannabinoid and terpene profiles in the various PIEX concentrates allows for patient-specific therapy.

With its PIEX THC concentrate, Becanex offers a long-term stable portfolio that includes both Indica and Sativa extracts. The THC content is standardised at 70%, while the CBD content is below 1%.

This allows us to meet the demand from doctors and patients for concentrates that correspond to the natural profile of the flower. The various PIEX THC concentrates differ in their terpene profiles – and thus in their different effect profiles. Each concentrate has a batch-stable, characterising terpene focus. In each batch, the five dominant terpenes that make up more than 70% of the total terpene content are identified. Depending on the source flower, the total terpene content is around 3.5% - all natural from the extracted cannabis flower, no added external terpenes.

CBD and CBD-concentrates are becoming increasingly important in cannabis therapy. In contrast to THC concentrates, however, little attention has been paid to the terpene profile of CBD-concentrate to date. Becanex sees great potential here for further improvement in treatment options.

Becanex is opening up new options with its PIEX CBD-concentrates: The CBD content is a stable 62%, while the THC content is below 5%. Each CBD-concentrate has its own clearly defined terpene profile. The five main terpenes account for over 70% of the total terpene content, which averages around 3%. In addition, the minor cannabinoids are reported separately for each batch.

In addition to THC and CBD, cannabis flowers contain complex terpene profiles that support the so-called entourage effect. We believe that cannabis concentrates should also have stable, characterising terpene profiles.

That is why Becanex's extended certificate of analysis (‘2+5 CoA’) not only shows the content of the main and minor cannabinoids, but also the content of the five dominant key terpenes in each batch. These represent more than 70 per cent of the total terpene content. The analysis creates additional transparency and enables doctors to tailor therapies even more precisely to the individual needs of their patients.